$SHC earnings report

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results. AlphAI read Sotera Health's Third quarter 2026 and nine months ended September 30, 2026 filing as solid. 2 quarters are on record below.

Third quarter 2026 and nine months ended September 30, 2026

AlphAI · Earnings readSHC · Third quarter 2026 and nine months ended September 30, 2026 · ended September 30, 2026

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results

✓Solid quarter

Third-quarter net revenues increased 4.4%, Adjusted EBITDA increased 3.9%, and Adjusted EPS increased 12% per diluted share. Sterigenics and Nelson Labs posted constant currency growth, while expected Co-60 harvest timing drove an 11.5% constant currency revenue decline at Nordion.

Revenue
$277M
Sterigenics Q3 2026
$209M
8.5% y/y
EPS · non-GAAP
$ 0.29
12% y/y
Full-Year 2026 Outlook outlook
Net revenues in the range of $1.233 billion to $1.250 billion, representing constant currency growth of 5.25% to 6.75%.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 service revenuesGAAP$277.1M––
Q3 2026 product revenuesGAAP$47.79M––
Q3 2026 total net revenuesGAAP$324.9M–4.4%
Q3 2026 total net revenues constant currency growthnon-GAAP4.4%–4.4%
Q3 2026 service cost of revenuesGAAP$127.1M––
Q3 2026 product cost of revenuesGAAP$17.00M––
Q3 2026 total cost of revenuesGAAP$144.1M––
Q3 2026 gross profitGAAP$180.8M––
Q3 2026 selling, general and administrative expensesGAAP$64.14M––
Q3 2026 amortization of intangible assetsGAAP$3.00M––
Q3 2026 interest expense, netGAAP$34.12M––
Q3 2026 loss on refinancing of debtGAAP—––
Q3 2026 foreign exchange gain, netGAAP−$1.09M––
Q3 2026 other income, netGAAP−$3.11M––
Q3 2026 income before income taxesGAAP$83.73M––
Q3 2026 provision for income taxesGAAP$25.34M––
Q3 2026 net incomeGAAP$58.39M––
Q3 2026 diluted earnings per shareGAAP$ 0.20––
Q3 2026 Adjusted Net Incomenon-GAAP$82.49M––
Q3 2026 Adjusted EBITDAnon-GAAP$170.7M–3.9%
Q3 2026 Adjusted EBITDA constant currency growthnon-GAAP4.0%–4.0%
Q3 2026 Adjusted EBITDA marginnon-GAAP52.5 %improved nearly 100 basis points–
Q3 2026 adjusted diluted earnings per sharenon-GAAP$ 0.29–12%
Nine months 2026 total net revenuesGAAP$926.3M––
Nine months 2026 gross profitGAAP$505.8M––
Nine months 2026 net incomeGAAP$138.6M––
Nine months 2026 diluted earnings per shareGAAP$ 0.48––
Nine months 2026 Adjusted EBITDAnon-GAAP$471.1M––
Nine months 2026 Adjusted EBITDA marginnon-GAAP50.9 %––
Nine months 2026 adjusted diluted earnings per sharenon-GAAP$ 0.72––

Segments

SegmentRevenueq/qy/y
Sterigenics Q3 2026Net revenues growth was driven by pricing, improved volume and mix, and a foreign currency benefit.$209M–8.5%
Nordion Q3 2026Unfavorable volume and mix due to the expected timing of Co-60 harvest schedules and foreign exchange were partially offset by favorable pricing.$55M–decrease of 12.4%
Nelson Labs Q3 2026Net revenues and segment income growth were driven by favorable volume and mix as well as pricing, partially offset by foreign exchange.$61M–8.8%
Sterigenics nine months 2026Segment income increased 9.6% to $332 million.$607M–8.9%
Nordion nine months 2026Segment income increased 8.2% to $85 million.$146M–6.1%
Nelson Labs nine months 2026Segment income decreased 2.4% to $54 million.$173M–4.9%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full-Year 2026 Outlook outlook

  • RevenueNet revenues in the range of $1.233 billion to $1.250 billion, representing constant currency growth of 5.25% to 6.75%.
  • Tax rateTax rate applicable to Adjusted Net Income remains in the range of 27.0% to 28.0%.
  • NoteAdjusted EBITDA in the range of $632 million to $641 million, representing constant currency growth of 5.75% to 7.25%.
  • NoteFull-year Adjusted EBITDA margins approximately flat versus 2025.
  • NoteThe foreign currency benefit to net revenues and Adjusted EBITDA has been revised to 70 basis points from 100 basis points in our previous outlook.
  • NoteInterest expense narrowed to a range of $137 million to $140 million.
  • NoteAdjusted EPS range remains in the range of $0.95 to $1.01.
  • NoteA weighted-average fully diluted share count remains in the range of 289 million to 291 million shares.
  • NoteCapital expenditures remain in the range of $200 million to $225 million.

What drove it

  • Sterigenics delivered 8.2% constant currency revenue growth in the third quarter, supported by pricing, improved volume and mix.
  • Nelson Labs delivered 9.2% constant currency revenue growth in the third quarter, supported by favorable volume and mix as well as pricing.
  • Nordion third-quarter revenue was affected by expected Co-60 harvest timing, with unfavorable volume and mix and foreign exchange partially offset by favorable pricing.
  • Nordion segment income margin improved due to operational productivity and favorable pricing, partially offset by inflation.
  • A new Nelson Labs Annex-1 compliant cleanroom was completed during the quarter.

Concerns

  • Nordion third-quarter constant currency revenue declined 11.5% due to expected Co-60 harvest timing.
  • Nelson Labs third-quarter segment income increased 2.5%, while its segment income margin was impacted primarily by business mix.
  • The foreign currency benefit to full-year net revenues and Adjusted EBITDA was revised to 70 basis points from 100 basis points.
  • The outlook is based on expectations regarding supply chain continuity, particularly for the supply of ethylene oxide and Co-60, and the impact of inflationary trends.
  • The company identifies litigation related to EO emissions and releases, leverage, regulatory requirements, material availability, inflation, and foreign currency exchange rates among its risks.

What to watch

  • Full-year delivery against net revenue guidance of $1.233 billion to $1.250 billion and Adjusted EBITDA guidance of $632 million to $641 million.
  • Nordion revenue progression as Co-60 harvest schedules affect volume and mix.
  • Whether full-year Adjusted EBITDA margins are approximately flat versus 2025.
  • Capital expenditures within the guided range of $200 million to $225 million.
  • Net Leverage following the reported improvement to 2.9x and the Moody's Ratings credit rating upgrade in early October.

Balance sheet and cash flow

  • As of September 30, 2026, total debt was $2.2 billion and unrestricted cash and cash equivalents were $412 million.
  • Total Debt was $ 2,244,260 (in thousands) as of September 30, 2026, compared to $ 2,237,997 (in thousands) as of December 31, 2025.
  • Cash and cash equivalents were $ 412,393 (in thousands) as of September 30, 2026, compared to $ 346,456 (in thousands) as of December 31, 2025.
  • Net Debt was $ 1,831,876 (in thousands) as of September 30, 2026, compared to $ 1,893,376 (in thousands) as of December 31, 2025.
  • Net Leverage was 2.9x as of September 30, 2026, compared to 3.2x as of December 31, 2025.
  • Q3 2026 net cash provided by operating activities was $111 million.
  • Nine months 2026 net cash provided by operating activities was $ 228,479 (in thousands), compared to $ 184,091 (in thousands).
  • Nine months 2026 purchases of property, plant and equipment were $ (145,450) (in thousands), compared to $ (87,319) (in thousands).
  • Nine months 2026 net cash used in investing activities was $ (140,175) (in thousands), compared to $ (84,445) (in thousands).
  • Nine months 2026 payments on long-term borrowings were $ (7,097) (in thousands), compared to $ (82,547) (in thousands).
  • Nine months 2026 net cash used in financing activities was $ (16,978) (in thousands), compared to $ (92,359) (in thousands).

Analysis

Sotera Health reported third-quarter 2026 total net revenues of $324,886 (in thousands), compared with $311,312 (in thousands) in the prior-year quarter, with the release describing 4.4% growth both as reported and on a constant currency basis. Net income was $58,391 (in thousands), compared with $48,400 (in thousands), while diluted earnings per share were $0.20 versus $0.17. Adjusted EBITDA was $170,665 (in thousands), compared with $164,190 (in thousands), and adjusted diluted earnings per share increased to $0.29 from $0.26.

Segment trends were uneven but favorable overall. Sterigenics generated $209 million of third-quarter revenue, up 8.5%, or 8.2% on a constant currency basis, with growth attributed to pricing, improved volume and mix, and a foreign currency benefit. Nelson Labs generated $61 million, up 8.8%, or 9.2% on a constant currency basis, driven by favorable volume and mix and pricing. Nordion generated $55 million, a decrease of 12.4%, or 11.5% on a constant currency basis, due to expected Co-60 harvest timing.

Profitability reflected contrasting segment dynamics. Third-quarter Adjusted EBITDA margin was 52.5 %, compared with 52.7 % in the prior-year quarter, while management said sequential Adjusted EBITDA margin improved nearly 100 basis points. Sterigenics segment income improved 9.6% to $117 million and Nordion segment income margin improved through operational productivity and favorable pricing, partly offset by inflation. Nelson Labs segment income increased 2.5% to $19 million, with its segment income margin impacted primarily by business mix.

Cash generation and leverage continued to improve. The company reported $111 million of net cash provided by operating activities in the quarter and $228,479 (in thousands) in the first nine months. Net Debt was $1,831,876 (in thousands) as of September 30, 2026, compared with $1,893,376 (in thousands) as of December 31, 2025, while Net Leverage improved to 2.9x from 3.2x. Capital investment remained significant, with nine-month purchases of property, plant and equipment of $145,450 (in thousands).

Management reaffirmed its full-year revenue and Adjusted EBITDA outlook, calling for net revenues of $1.233 billion to $1.250 billion and Adjusted EBITDA of $632 million to $641 million. The company narrowed expected interest expense to $137 million to $140 million, retained its $0.95 to $1.01 Adjusted EPS range, and retained capital expenditure guidance of $200 million to $225 million. The foreign currency benefit to revenue and Adjusted EBITDA was revised to 70 basis points from 100 basis points in the previous outlook.

Management, verbatim

We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion.

Alton Shader, Chief Executive Officer

Based on our year-to-date performance and expectations for the remainder of the year, we are reaffirming our 2026 constant currency revenue and Adjusted EBITDA outlook.

Alton Shader, Chief Executive Officer

Not in the filing

stated, not guessed
  • GAAP operating income was not reported.
  • GAAP gross margin was not reported.
  • Free cash flow was not reported.
  • Third-quarter capital expenditures were not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readSHC · Q2 2026 · ended June 30, 2026

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

✓Strong quarter

Q2 net revenues increased 9.2%, Adjusted EBITDA increased 10.0%, Adjusted EPS increased 30%, all three operating segments posted revenue growth, and the Company raised its full-year 2026 net revenues and Adjusted EBITDA outlook.

Revenue
9.2%
9.2% y/y
Sterigenics
$212M
8.6% y/y
EPS · GAAP
$0.19
FY 2026 outlook
$1.236 billion to $1.254 billion, representing constant currency growth of 5.25% to 6.75% and an estimated 100 basis points of foreign currency benefit

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q2 2026 net revenues growthGAAP9.2%–9.2%
Q2 2026 net revenues growth, constant currency basisnon-GAAP8.0%–8.0%
Q2 2026 net incomeGAAP$54M––
Q2 2026 diluted earnings per shareGAAP$0.19 per diluted share––
Q2 2026 Adjusted EBITDA growthnon-GAAP10.0%–10.0%
Q2 2026 Adjusted EBITDA growth, constant currency basisnon-GAAP8.7%–8.7%
Q2 2026 Adjusted EBITDA marginnon-GAAP51.6%––
Q2 2026 Adjusted EPSnon-GAAP$0.26–30%
Q2 2026 net cash provided by operating activitiesGAAP$88M––
June 30, 2026 Net Leverage Rationon-GAAP3.0x––
Sterigenics Q2 2026 segment incomeother$118M–9.6%
Sterigenics first six months of 2026 segment incomeother$215M–9.6%
Nordion Q2 2026 segment incomeother$28M–19.2%
Nordion first six months of 2026 segment incomeother$52M–26.4%
Nelson Labs Q2 2026 segment incomeother$20M–0.6%
Nelson Labs first six months of 2026 segment incomeother$34M–-4.9%

Segments

SegmentRevenueq/qy/y
SterigenicsSecond-quarter net revenues growth was driven by favorable pricing, improved volume/mix and a foreign currency benefit.$212M–8.6%
NordionSecond-quarter net revenues growth was driven by improved volume/mix, primarily due to the timing of Cobalt-60 harvests and favorable pricing, partially offset by foreign currency.$49M–15.8%
Nelson LabsSecond-quarter net revenues and segment income growth were driven by favorable pricing, improved volume/mix and a foreign currency benefit.$61M–6.3%
Sterigenics, first six months of 2026Constant currency net revenues increased 6.6%.$398M–9.1%
Nordion, first six months of 2026Constant currency net revenues increased 20.8%.$91M–21.6%
Nelson Labs, first six months of 2026Constant currency net revenues improved 0.9%.$113M–2.9%

FY 2026 outlook

  • Revenue$1.236 billion to $1.254 billion, representing constant currency growth of 5.25% to 6.75% and an estimated 100 basis points of foreign currency benefit
  • Tax rate27.0% to 28.0%
  • NoteAdjusted EBITDA range raised to $634 million to $643 million, representing constant currency growth of 5.75% to 7.25% and an estimated 100 basis points of foreign currency benefit
  • NoteInterest expense improved to a range of $135 million to $142 million
  • NoteAdjusted EPS improved to a range of $0.95 to $1.01
  • NoteA weighted-average fully diluted share count in the range of 289 million to 291 million shares
  • NoteCapital expenditures in the range of $200 million to $225 million

What drove it

  • Sterigenics revenue growth reflected favorable pricing, improved volume/mix and a foreign currency benefit.
  • Nordion growth reflected improved volume/mix, primarily due to the timing of Cobalt-60 harvests, and favorable pricing, partially offset by foreign currency.
  • Nelson Labs growth reflected favorable pricing, improved volume/mix and a foreign currency benefit.
  • All three business units reported revenue growth in Q2 2026.
  • The Company cited strong first-half performance and confidence in the remainder of the year in raising its full-year 2026 outlook.

Concerns

  • Nelson Labs segment income margin was impacted by higher costs.
  • Inflation partially offset segment income and segment income margin benefits at Sterigenics and Nordion.
  • The outlook incorporates assumptions regarding supply chain continuity, particularly for the supply of ethylene oxide and Cobalt-60, and inflationary trends affecting energy prices and labor supply.
  • The Company identified potential uncertainty from changes to the regulatory landscape, restructuring items and certain fair value measurements.
  • The filing cites risks related to ethylene oxide litigation, environmental, health and safety regulations, supply availability, foreign currency exchange rates, inflation and tariffs.

What to watch

  • Execution against the raised FY 2026 net revenues range of $1.236 billion to $1.254 billion.
  • Execution against the raised FY 2026 Adjusted EBITDA range of $634 million to $643 million.
  • Whether Nelson Labs can improve its segment income margin following the impact from higher costs.
  • Availability and pricing of ethylene oxide and Cobalt-60.
  • Progress in maintaining the long-term net leverage ratio target range of 2.0x to 3.0x.
  • Capital expenditures in the range of $200 million to $225 million.

Balance sheet and cash flow

  • Net cash provided by operating activities of $88 million
  • As of June 30, 2026, Sotera Health had $2.2 billion of total debt, and $357 million in unrestricted cash and cash equivalents.
  • As of December 31, 2025, Sotera Health had $2.2 billion in total debt and $345 million in unrestricted cash and cash equivalents.
  • Available liquidity increased to approximately $950 million.
  • The Company had no outstanding borrowings under its $600 million revolving credit facility.
  • Repriced term loan, saving approximately $3.5 million of annual interest expense.
  • Net Leverage Ratio improved to 3.0x, achieving the Company’s long-term net leverage ratio target range of 2.0x to 3.0x.

Analysis

Sotera Health reported broad Q2 growth, with net revenues increasing 9.2%, or 8.0% on a constant currency basis. Net income was $54 million, compared to $8 million in Q2 2025, while diluted earnings per share were $0.19 per diluted share, compared to $0.03 per diluted share. Adjusted EBITDA increased 10.0%, or 8.7% on a constant currency basis, and the Adjusted EBITDA margin expanded to 51.6%. Adjusted EPS was $0.26, up 30% per diluted share.

All three segments contributed to revenue growth. Sterigenics net revenues increased 8.6% to $212 million, supported by favorable pricing, improved volume/mix and foreign currency. Nordion was the fastest-growing segment, with net revenues up 15.8% to $49 million, driven by volume/mix associated primarily with the timing of Cobalt-60 harvests and favorable pricing. Nelson Labs net revenues grew 6.3% to $61 million, with pricing, volume/mix and foreign currency contributing.

Profitability improved most visibly at Sterigenics and Nordion. Sterigenics segment income increased 9.6% to $118 million and Nordion segment income increased 19.2% to $28 million. Nelson Labs segment income increased 0.6% to $20 million, but its segment income margin was impacted by higher costs. For the first six months of 2026, Nelson Labs segment income decreased 4.9% to $34 million despite net revenue growth of 2.9% to $113 million, making cost recovery and margin progression at that business a key operating focus.

Cash generation and leverage improved. Net cash provided by operating activities was $88 million. The Company ended June 30, 2026 with $2.2 billion of total debt and $357 million in unrestricted cash and cash equivalents, while available liquidity increased to approximately $950 million. The Net Leverage Ratio improved to 3.0x, reaching the stated long-term target range of 2.0x to 3.0x. Sotera Health also repriced its term loan, saving approximately $3.5 million of annual interest expense.

Management raised full-year 2026 net revenues guidance to $1.236 billion to $1.254 billion and Adjusted EBITDA guidance to $634 million to $643 million. The outlook calls for constant currency net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%, each with an estimated 100 basis points of foreign currency benefit. The guide also includes interest expense of $135 million to $142 million, a tax rate applicable to Adjusted Net Income of 27.0% to 28.0%, Adjusted EPS of $0.95 to $1.01, and capital expenditures of $200 million to $225 million.

Management, verbatim

We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units.

Alton Shader, Chief Executive Officer

Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook.

Alton Shader, Chief Executive Officer

Not in the filing

stated, not guessed
  • Q2 2026 total net revenues dollar amount
  • Q2 2026 total net revenues prior-year dollar amount
  • Q2 2026 GAAP gross profit and gross margin
  • Q2 2026 GAAP operating income and operating margin
  • Q2 2026 Adjusted EBITDA dollar amount
  • Q2 2026 Adjusted EBITDA prior-year dollar amount
  • Q2 2026 Adjusted EPS prior-year value
  • Q2 2026 free cash flow
  • Quarterly capital expenditures
  • Share repurchases and dividends
  • Prior-quarter consolidated comparisons
  • Previous-release outlook for comparison
  • Forward gross margin guidance
  • Forward operating expenses guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SHC earnings dates

When is Sotera Health's next earnings date?
AlphAI has no date for SHC yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.